These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23625593)

  • 1. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
    Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
    PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
    Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
    Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
    Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
    van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
    Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
    Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
    Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
    Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
    Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
    Gudlaugsson E; Skaland I; Janssen EA; Smaaland R; Shao Z; Malpica A; Voorhorst F; Baak JP
    Histopathology; 2012 Dec; 61(6):1134-44. PubMed ID: 22963617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer.
    Skaland I; Janssen EA; Gudlaugsson E; Hui Ru Guo L; Baak JP
    Cell Oncol; 2009; 31(4):261-71. PubMed ID: 19633363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
    Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
    Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
    Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
    Finsterbusch K; Decker T; van Diest PJ; Focke CM
    Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3.
    Ohashi R; Namimatsu S; Sakatani T; Naito Z; Takei H; Shimizu A
    J Surg Oncol; 2018 Sep; 118(3):557-567. PubMed ID: 30098295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.